Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer immunotherapy.

S P Richman, J U Gutterman, E M Hersh

    Canadian Medical Association Journal
    |February 3, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Cancer immunotherapy research was advanced by tumor antigens, bacille Calmette-Guérin (BCG) protection, and immune depression insights. Trials using microbial agents and active specific immunotherapy with BCG showed prolonged survival in cancer patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2015
    Same author

    Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2.

    Cancer immunology, immunotherapy : CII·2001
    Same author

    Cationic lipid-mediated gene transfer: current concepts.

    Current opinion in molecular therapeutics·2001
    Same author

    Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2001
    Same author

    Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators.

    Anti-cancer drugs·2001
    Same author

    A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors.

    Cancer chemotherapy and pharmacology·2001
    Same journal

    Tularaemia; a problem in diagnosis.

    Canadian Medical Association journal·2010
    Same journal

    CONTROL of cancer.

    Canadian Medical Association journal·2010
    Same journal

    Bilateral diphtheritic external otitis treated with sulfathiazole.

    Canadian Medical Association journal·2010
    Same journal

    Hypoplastic anaemia treated with transfusions and folic acid fraction.

    Canadian Medical Association journal·2010
    Same journal

    Lauron in rheumatoid arthritis; a further report.

    Canadian Medical Association journal·2010
    Same journal

    HOW the socialist looks at national health service in England.

    Canadian Medical Association journal·2010
    See all related articles

    Area of Science:

    • Immunology
    • Oncology
    • Cancer Research

    Background:

    • Key discoveries driving cancer immunotherapy include tumor-associated antigens, bacille Calmette-Guérin (BCG) mediated tumor protection in animals, and the link between immunodepression and prognosis in malignant diseases.
    • Early immunotherapy trials explored local and systemic effects using microbial agents, with combinations of tumor cell-based vaccines and non-specific adjuvants like BCG.

    Purpose of the Study:

    • To review the foundational contributions and evolving strategies in cancer immunotherapy.
    • To highlight the therapeutic potential of microbial agents and active specific immunotherapy in cancer treatment.

    Main Methods:

    • Review of historical contributions and clinical trial methodologies in cancer immunotherapy.
    • Analysis of therapeutic approaches involving microbial agents (e.g., BCG) and active specific immunotherapy (tumor cells/extracts) combined with adjuvants.

    Related Experiment Videos

  • Evaluation of recent studies utilizing immunomodulatory drugs like thymosin and levamisole.

    • Main Results:

    • Cancer immunotherapy research has been significantly stimulated by the identification of tumor antigens and the immunomodulatory effects of agents like BCG.
    • Trials combining active specific immunotherapy with adjuvants such as BCG have been a common strategy.
    • Recent studies indicate that thymosin and levamisole can prolong survival in patients with lung cancer and other malignancies.

    Conclusions:

    • The integration of microbial agents and active specific immunotherapy, often with BCG, represents a significant area of cancer treatment research.
    • Emerging evidence supports the use of agents like thymosin and levamisole for improving survival outcomes in cancer patients.